Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 476,053
  • Shares Outstanding, K 363,399
  • Annual Sales, $ 31,080 K
  • Annual Income, $ -200,400 K
  • EBIT $ -67 M
  • EBITDA $ -64 M
  • 60-Month Beta 0.71
  • Price/Sales 6.76
  • Price/Cash Flow N/A
  • Price/Book 4.14

Options Overview Details

View History
  • Implied Volatility 125.22% (+34.84%)
  • Historical Volatility 67.97%
  • IV Percentile 7%
  • IV Rank 7.45%
  • IV High 558.03% on 02/24/25
  • IV Low 90.38% on 01/20/26
  • Expected Move (DTE 30) 0.3570 (22.88%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 2,375
  • Volume Avg (30-Day) 646
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 24,677
  • Open Int (30-Day) 34,536
  • Expected Range 1.2030 to 1.9170

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.07
  • Number of Estimates 3
  • High Estimate -0.07
  • Low Estimate -0.08
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1100 +40.54%
on 01/12/26
1.6500 -5.45%
on 01/21/26
+0.3900 (+33.33%)
since 12/19/25
3-Month
1.1100 +40.54%
on 01/12/26
1.6500 -5.45%
on 01/21/26
+0.1200 (+8.33%)
since 10/21/25
52-Week
0.2800 +457.14%
on 03/03/25
1.6600 -6.02%
on 10/10/25
+0.7717 (+97.89%)
since 01/21/25

Most Recent Stories

More News
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S....

LXRX : 1.5600 (+19.08%)
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027 $10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851 Zynquista...

LXRX : 1.5600 (+19.08%)
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” 

-White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies- -Need for swift action by policymakers...

LXRX : 1.5600 (+19.08%)
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare...

LXRX : 1.5600 (+19.08%)
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as...

LXRX : 1.5600 (+19.08%)
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin...

LXRX : 1.5600 (+19.08%)
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler...

LXRX : 1.5600 (+19.08%)
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

THE WOODLANDS, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Jefferies 2025...

LXRX : 1.5600 (+19.08%)
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific...

LXRX : 1.5600 (+19.08%)
Lexicon: Q3 Earnings Snapshot

Lexicon: Q3 Earnings Snapshot

LXRX : 1.5600 (+19.08%)

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

3rd Resistance Point 2.0167
2nd Resistance Point 1.8333
1st Resistance Point 1.6967
Last Price 1.5600
1st Support Level 1.3767
2nd Support Level 1.1933
3rd Support Level 1.0567

See More

52-Week High 1.6600
Last Price 1.5600
Fibonacci 61.8% 1.1328
Fibonacci 50% 0.9700
Fibonacci 38.2% 0.8072
52-Week Low 0.2800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar